On May 17, 2017 Kite Pharma, Inc. (Nasdaq:KITE) reported new data presentations from multiple studies related to its lead investigational candidate, axicabtagene ciloleucel (also known as KTE-C19), at the 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, IL, June 2-6, 2017 (Press release, Kite Pharma, MAY 17, 2017, View Source [SID1234519191]). The full text for abstracts is available online through the ASCO (Free ASCO Whitepaper) website at View Source
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
“The presentations at ASCO (Free ASCO Whitepaper) continue to enhance our growing knowledge on the potential for cell therapy,” said David Chang, M.D., Ph.D., Executive Vice President of Research and Development and Chief Medical Officer of Kite. “The translational insights from these data presentations are invaluable as we advance axicabtagene ciloleucel/KTE-C19 and seek to optimize treatment, not only in NHL, but also across a broad range of hematologic malignancies.”
Poster Discussion:
Clinical and biologic covariates of outcomes in ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL)
Abstract #7512
Session: Poster Session: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
Poster Board #274
Session Time/Location: Monday, June 5, 2017: 8:00-11:30 AM CDT, Hall A
Poster Discussion Session Time/Location: Monday, June 5, 2017: 1:15-2:30 PM CDT, E354b
Presenter: Frederick L. Locke, M.D., Moffitt Cancer Center, Tampa, FL
Poster Presentations
Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL)
Abstract #3024
Session: Poster Session: Developmental Therapeutics – Immunotherapy
Poster Board #119
Session Time/Location: Monday, June 5, 2017: 8:00-11:30 AM CDT, Hall A
Presenter: Bijal D. Shah, M.D., Moffitt Cancer Center, Tampa, FL
Product characteristics associated with in vivo expansion of anti-CD19 CAR T cells in patients treated with axicabtagene ciloleucel (axi-cel)
Abstract #3023
Session: Poster Session: Developmental Therapeutics – Immunotherapy
Poster Board #118
Session Time/Location: Monday, June 5, 2017: 8:00-11:30 AM CDT, Hall A
Presenter: Frederick L. Locke, M.D., Moffitt Cancer Center, Tampa, FL
Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19)
Abstract #3025
Session: Poster Session: Developmental Therapeutics – Immunotherapy
Poster Board #120
Session Time/Location: Monday, June 5, 2017: 8:00-11:30 AM CDT, Hall A
Presenter: Jerome Galon, Ph.D., Laboratory of Integrative Cancer Immunology, INSERM
ZUMA-6: Phase 1-2 multicenter study evaluating safety and efficacy of axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab in patients with refractory diffuse large B-cell lymphoma (DLBCL)
Abstract #TPS7572
Session: Trials in Progress Poster Session: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
Poster Board #331a
Session Time/Location: Monday, June 5, 2017: 8:00-11:30 AM CDT, Hall A
Presenter: Frederick L. Locke, M.D., Moffitt Cancer Center, Tampa, FL
Online Publication
Total 1-year cost of diffuse large B-cell lymphoma (DLBCL) beyond first-line (1L) therapy: A retrospective cohort analysis
Abstract # e18333
Senior Author: Anna Purdum, PharmD, M.S., Kite Pharma
About axicabtagene ciloleucel
Kite’s lead product candidate, axicabtagene ciloleucel, previously known as KTE-C19, is an investigational therapy in which a patient’s T cells are engineered to express a chimeric antigen receptor (CAR) to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias, and redirect the T cells to kill cancer cells. Axicabtagene ciloleucel has been granted Breakthrough Therapy Designation status for diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL) by the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) regulatory support for DLBCL in the EU.